Lu AA41063
Lu AA41063 is a selective adenosine A2A receptor antagonist. Structurally, it is a non-xanthine.
The affinities of the drug for the human adenosine receptors are 5.9nM for the adenosine A2A receptor, 410nM for the adenosine A1 receptor, 260nM for the adenosine A2B receptor, and >10,000nM for the adenosine A3 receptor.
Lu AA41063 was first described in the scientific literature by 2014.
Lu AA47070, a water-soluble phosphate ester prodrug of Lu AA41063, is orally active and was under development for the treatment of Parkinson's disease but was discontinued. In addition to its antiparkinsonian-like effects, Lu AA47070 reverses motivational deficits in animals and hence shows pro-motivational effects.